Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 45 WIGGINS AVENUE BEDFORD MA 01730 |
Tel: | N/A |
Website: | https://www.stoketherapeutics.com |
IR: | See website |
Key People | ||
Edward M. Kaye Chief Executive Officer, Director | Stephen J. Tulipano Chief Financial Officer | Huw M. Nash Chief Operating Officer, Chief Business Officer |
Jonathan Allan General Counsel, Company Secretary | Barry S. Ticho Chief Medical Officer |
Business Overview |
Stoke Therapeutics, Inc. is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with ribonucleic acid-based medicines. Using its Targeted Augmentation of Nuclear Gene Output (TANGO) approach, the Company is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both the occurrence of seizures and non-seizure comorbidities. Its STK-002 is a ASO in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene. |
Financial Overview |
For the fiscal year ended 31 December 2023, Stoke Therapeutics Inc revenues decreased 29% to $8.8M. Net loss increased 4% to $104.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 5% to $72.3M (expense), Stock-based Compensation in SGA increase of 10% to $15.3M (expense). |
Employees: | 110 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $423.71M as of Dec 31, 2023 |
Annual revenue (TTM): | $8.78M as of Dec 31, 2023 |
EBITDA (TTM): | -$112.30M as of Dec 31, 2023 |
Net annual income (TTM): | -$104.70M as of Dec 31, 2023 |
Free cash flow (TTM): | -$82.68M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 46,303,743 as of Mar 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |